Insights+: The US FDA New Drug Approvals in June 2022

The US FDA approved 2 NDAs and 2 BLA in June 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 37 novel products in 2022 In June 2022, the major highlights drugs were Amvuttra's approval for polyneuropathy of hereditary transthyretin-mediated amyloidosis, Skyrizi for active Crohn's disease, Olumiant…

BySenior EditorJuly 21, 2022

INSIGHTS+

Insights+ Key Biosimilars Events of April 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of April, Alvotech resolved a European patent dispute with…

BySenior EditorMay 5, 2022

INSIGHTS+

Insights+: The US FDA New Drug Approvals in March 2022

The US FDA has approved 9 NDAs and 1 BLAs in Mar 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 20 novel products in 2022 In Mar 2022, the major highlights drugs were Adlarity for Alzheimer's Disease, Rinvoq for Ulcerative Colitis, Ztalmy for CDKL5 Deficiency Disorder…

BySenior EditorApril 21, 2022

TOP 20

Top 20 BioPharma Companies based on 2021 Total Revenue

While the COVID-19 pandemic has dominated the healthcare space for the last two years, some biopharma companies were involved in multiple deals, M&A, and the development of various drug candidates in other areas to diversify their portfolios While top Biopharma companies remain on the chart, however, in 2021, new players like Moderna, BioNTech, Viatris also…

ByPrince GiriApril 14, 2022

INSIGHTS+

Insights+ Key Biosimilars Events of March 2022

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of March, Junshi & Mabwell Bioscience’s Junmaikang (biosimilar, adalimumab)…

BySenior EditorApril 7, 2022

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2022

The first quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include Biocon acquired Viatris’ biosimilars assets for ~$3.335B, Stryker signed a definitive agreement to acquire Vocera Communications for ~$3.09B, Biohaven acquire Channel Biosciences for ~$3B The first quarter of the year also showcases regulatory events…

BySenior EditorMarch 31, 2022

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2021

The third quarter of 2021 highlights the approvals, clinical data & acquisitions. The new alliance observed in third quarter includes AzurRx signed a reverse triangular merger agreement to acquired First Wave Bio for ~$229M The key highlights of the big acquisition in this quarter includes Merck acquired Acceleron for ~$11.5B, Baxter acquired Hillrom for ~$10.5B,…

BySenior EditorSeptember 30, 2021

TOP 20

Top 20 Oncology Companies Based on 2020 Oncology Segment Revenue

Oncology is a rapidly evolving therapy area and all of the top Biopharma players are investing in the research and development of cancer therapies. In 2020- the world witnessed a major acquisition of Immunomedic by Gilead of $21B for Trodelvy Our team at PharmaShots has compiled a list of top 20 oncology companies based on…

ByPrince GiriSeptember 9, 2021

TOP 20

Top 20 Immunology Companies Based on 2020 Immunology Segment Revenue

Immunology deals with the physiological functioning of the immune system in states of both health and disease as well as malfunctions of the immune system in immunological disorders With the new advancement in the immune sector- global pharmaceuticals continue to grow in the field despite the disruption during COVID-19. As in 2019- Abbvie again secured…

ByPrince GiriAugust 12, 2021

TOP 20

Top 20 BioPharma Companies based on 2020 Total Revenue

Despite having the global Covid-19 pandemic- the biopharma companies were involved in multiple M&A and licensing deals. The major focus of the year remains the production and distribution of vaccines to combat the COVID-19 globally All of the Biopharma companies on our list are on the front line to combat this global crisis. The top…

ByPrince GiriApril 8, 2021

Insights+: The US FDA New Drug Approvals in June 2022

Insights+ Key Biosimilars Events of April 2022

Insights+: The US FDA New Drug Approvals in March 2022

Top 20 BioPharma Companies based on 2021 Total Revenue

Insights+ Key Biosimilars Events of March 2022

PharmaShots’ Key Highlights of First Quarter 2022

PharmaShots’ Key Highlights of Third Quarter 2021

Top 20 Oncology Companies Based on 2020 Oncology Segment Revenue

Top 20 Immunology Companies Based on 2020 Immunology Segment Revenue

Top 20 BioPharma Companies based on 2020 Total Revenue

Contact US

FOLLOW US